Neoadjuvant chemotherapy for locally advanced cervical cancer

Iwata, Takashi; Miyauchi, Azumi; Suga, Yasuhiro; Nishio, Hiroshi; Nakamura, Masaru; Ohno, Akiko; Hirao, Nobumaru; Morisada, Tohru; Tanaka, Kyoko; Ueyama, Hiroki; Watari, Hidemichi; Aoki, Daisuke

doi:10.21147/j.issn.1000-9604.2016.02.13

Cited by 20 publications

(16 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Colo do útero Neoadjuvante, Adjuvante, terapia definitiva, terapia combinada, tratamento metastático, segunda linha. ROSE et al, 1999;GREEN et al, 2001;BENEDETTI-PANICI et al, 2002;RAHAMAN et al, 2009;ASANO;DAWOOD;INSTONE;KEHOE, 2013;TODO;WATARI, 2016;IWATA et al, 2016 Câncer de ovário Neoadjuvante, Adjuvante, terapia em estágio avançado, primeira linha, terapia combinada LUND et al, 1990;PICCART et al, 2000;HÖGBERG;GLIMELIUS;NYGREN, 2001;MARKMAN et al, 2001;OZOLS et al, 2003;ARMSTRONG et al, 2006;HELM;STATE, 2009;BERGAMINI et al, 2017 Câncer endometrial Adjuvante, terapia combinada DUNTON et al, 1991;FUJIMURA et al, 2000;AAPRO et al, 2003;RANDALL et al, 2006;SUSUMU et al, 2008;GALAAL et al, 2014; Câncer de vulva Neoadjuvante, adjuvante, terapia combinada, terapia metastática SHIMIZU et al, 1990;BEREK et al, 1991;BENEDETTI-PANICI et al, 1993;BELLATI et al, 2005;GEISLER;MANHAN;BULLER, 2006;RICHARD et al, 2008;CORMIO et al, 2009;ARAGONA et al, 2012; Câncer de vagina Neoadjuvante, Adjuvante, terapia combinada, terapia metastática ROBERT et al, 1991;...…”

Section: Cisplatinaunclassified

Avanços na quimioterapia do câncer ginecológico: uma revisão

Lima

Silva

Campelo

et al. 2020

BJD

View full text Add to dashboard Cite

show abstract

Section: Cisplatinaunclassified

Avanços na quimioterapia do câncer ginecológico: uma revisão

Lima

Silva

Campelo

et al. 2020

BJD

View full text Add to dashboard Cite

show abstract

“…Several other agents and drug combinations, including the taxanes, have been investigated as radiation sensitisers in CC. The most recent review of 13 different chemotherapy regimens concomitant to RT in the treatment of LACC indicated that CCRT with cisplatin/docetaxel might be the most effective (39). However, weekly cisplatin remains the least toxic among all chemotherapy regimens in combination with RT.…”

Section: Cytotoxic Agents Used In Combination With Rtmentioning

confidence: 99%

Systemic therapy for cervical carcinoma – current status

Serkies

Jassem

2018

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

Two major treatment modalities in cervical cancer are radiation therapy (RT) and surgery. Chemotherapy continues to be the main form of systemic therapy adjunctive to definitive local therapies, and is used for palliation. Platinum-based regimens, administered concurrently with both definitive and postoperative RT, were demonstrated to provide significant survival benefits, whereas the beneficial effect of concurrent chemoradiotherapy in later-stage disease was smaller. The role of chemotherapy in addition to RT in IB1/IIA1 cervical cancer patients not undergoing surgery remains undefined. Likewise, the role of chemotherapy in combination with postoperative RT for patients with intermediate-risk factors for recurrence has not yet been verified. The recent standard for chemoradiotherapy is cisplatin alone administered weekly. Other cisplatin-based or non-cisplatin-based regimens have not been subjected to large clinical studies. The benefits of consolidation chemotherapy after chemoradiation for locally advanced cervical cancer are still undetermined. Neoadjuvant cisplatin-based chemotherapy followed by surgery has shown survival benefits, however its role in the era of chemoradiotherapy remains unclear. The combination of cisplatin and paclitaxel is considered a standard regimen in the palliative setting. There is no standard of care for second-line systemic therapy in advanced cervical cancer. Bevacizumab combined with palliative chemotherapy (cisplatin/paclitaxel or topotecan/paclitaxel) in the first-line treatment for recurrent/metastatic cervical cancer significantly improves overall survival when compared to chemotherapy alone. The role of immunotherapy in cervical cancer remains to be established. The optimal combined modality treatment including systemic therapy for cervical tumors of non-squamous histology remains a matter of debate. Ongoing accumulation of data on genomic and proteomic characteristics provides insight into the molecular heterogeneity of cervical cancer and paves the way for developing molecularly targeted therapies.

show abstract

“…In China, the incidence of cervical cancer has increased rapidly over the past 20 years ( 3 ). Surgery, radiotherapy and chemotherapy are currently the main treatment methods for cervical cancer ( 4 ). Although advances in these therapies have prolonged patient survival, the limitations of effective regimens are the resistance of tumor cells and their severe side effects ( 5 ).…”

Section: Introductionmentioning

confidence: 99%

Ginsenoside Rh2 inhibits HeLa cell energy metabolism and induces apoptosis by upregulating voltage‑dependent anion channel 1

et al. 2020

View full text Add to dashboard Cite

20(S)-Ginsenoside Rh2 [20(S)-GRh2], one of the main active components of Panax ginseng, induces apoptosis in a wide range of cancer cell types. The present study found that 20(S)-GRh2 reduces mitochondrial membrane potential, decreases adenosine triphosphate generation and induces reactive oxygen species in HeLa cervical cancer cells. In addition, 20(S)-GRh2 activated mitochondrion-dependent apoptosis and inhibited both mitochondrial oxidative phosphorylation and glycolysis in HeLa cells. It was found that voltage-dependent anion channel 1 (VDAC1) expression was significantly upregulated by 20(S)-GRh2 treatment, while hexokinase 2 expression was downregulated and segregated from the mitochondria. Furthermore, 20(S)-GRh2 promoted Bax transport from the cytoplasm to the mitochondria, and knockdown of VdAc1 inhibited Bax transport and apoptosis. These results suggest that VdAc1 is a novel target of 20(S)-GRh2. The present study provides a better understanding of the mechanistic link between cervical cancer metabolism and growth control, and these results may facilitate the development of new treatments for cervical cancer.

show abstract

Neoadjuvant chemotherapy for locally advanced cervical cancer

Cited by 20 publications

References 34 publications

Avanços na quimioterapia do câncer ginecológico: uma revisão

Avanços na quimioterapia do câncer ginecológico: uma revisão

Systemic therapy for cervical carcinoma – current status

Ginsenoside Rh2 inhibits HeLa cell energy metabolism and induces apoptosis by upregulating voltage‑dependent anion channel 1

Contact Info

Product

Resources

About